Treatment of histoplasmosis with MK-991 (L-743,872)

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 151-153

  Graybill, John R ^a,b   Najvar, Laura K ^a   Montalbo, Eleanor M ^a   Barchiesi, Francesco J ^a   Luther, Michael F ^b   Rinaldi, Michael G ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; INTRAPERITONEAL DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 0031983594     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.151     Document Type: Article

References (20)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, D. Krupa, V. B. Pikounis, H. Kropp, and K. Bartizal. 1995. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 39:1077-1081.
2. Anaissie, E. J., A. Gokaslan, R. Hachem, R. Rubin, G. Griffin, R. Robinson, J. Sobel, and G. P. Bodey. 1992. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin. Infect. Dis. 15:781-787.
3. Angiolella, L., N. Simonetti, and A. Cassone. 1994. The lipopeptide antimycotic cilofungin modulates the incorporation of glucan-associated proteins into the cell wall of Candida albicans. J. Antimicrob. Chemother. 33:1137-1146.
4. Bartizal, K., T. Scott, G. K. Abruzzo, C. J. Gill, C. Pacholok, L. Lynch, and H. Kropp. 1995. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob. Agents Chemother. 39:1070-1076.
5. Beaulieu, D., J. Tang, D. J. Zeckner, and T. R. Parr, Jr. 1993. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-β-D-glucan synthase. FEMS Microbiol. Lett. 108:133-138.
6. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
7. Espinel-Ingroff, A. 1996. In vitro studies with L-743,872, a water soluble pneumocandin: a comparative study, abstr. F31, p. 105. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
9. Graybill, J. R., E. Palou, and J. Ahrens. 1986. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am. Rev. Respir. Dis. 134:768-770.
10. Hajdu, R., B. Pelak, J. Sundelof, R. Thompson, H. Rosen, and H. Kropp. 1996. Pharmacokinetics of L-743,872 in the mouse, rat, rhesus and chimpanzee, abstr. F44, p. 107. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Hall, G. S., C. Myles, K. J. Pratt, and J. A. Washington. 1988. Cilofungin (LY121019), and antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. 32:1331-1335.
12. Kobayashi, G. S., S. J. Travis, and G. Medoff. 1987. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice. Antimicrob. Agents Chemother. 31:2005-2006.
13. Kurtz, M. B., C. Douglas, J. Marrinan, K. Nollstadt, J. Onishi, S. Dreikorn, J. Milligan, S. Mandala, J. Thompson, J. M. Balkovec, F. A. Bouffard, J. F. Dropinski, M. L. Hammond, R. A. Zambias, G. Abruzzo, K. Bartizal, O. B. McManus, and M. L. Garcia. 1994. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother. 38:2750-2757.
14. Merck & Co., Inc. Data on file.
15. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts: proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Norris, S., J. Wheat, D. McKinsey, D. Lancaster, B. Katz, J. Black, M. Driks, R. Baker, K. Israel, D. Traeger, S. Moriarity, J. Fraiz, D. Webb, and T. Slama. 1994. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am. J. Med. 96: 504-508.
17. Wheat, J. 1994. Histoplasmosis: recognition and treatment. Clin. Infect. Dis. 19(Suppl. 1):S19-S27.
18. Wheat, J., R. Hafner, A. H. Korzun, M. T. Limjoco, P. Spencer, R. A. Larsen, F. M. Hecht, W. Powderly, and AIDS Clinical Trial Group. 1995. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98:336-342.
19. Wheat, L. J., R. Hafner, M. Wulfsohn, P. Spencer, K. Squires, W. Powderly, B. Wong, M. G. Rinaldi, M. Saag, R. Hamill, R. Murphy, P. A. Connolly-Springfield, N. Briggs, S. Owens, and NIAID Clinical Trials and Mycoses Study Group. 1993. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118:610-616.
20. Williams, D. M., J. R. Graybill, and D. J. Drutz. 1979. Experimental chemotherapy of histoplasmosis in nude mice. Am. Rev. Respir. Dis. 120:837-842.